GlassScriptPhysician profile
Michelle Fox Huffaker
NPI 1407141641
$5,789.48
in general payments reported to CMS, 2019-2025
15 companies · $2,048 in 2025
The $2,048 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $844 · 2020: $132 · 2021: $2,680 · 2022: $65.99 · 2023: $18.53 · 2025: $2,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,966 · Food and Beverage: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,966.25 |
| Food and Beverage | $100.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,667.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,048.18 | 2025 | Takhzyro, Eohilia |
| Teva Pharmaceuticals USA, INC. | $246.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $165.99 | 2019-2020 | |
| Alk-Abello, INC | $157.82 | 2019-2020 | |
| Glaxosmithkline, LLC. | $128.89 | 2019-2023 | Nucala |
| Novartis Pharmaceuticals Corporation | $88.10 | 2019 | |
| Genentech USA, INC. | $65.99 | 2022 | |
| Covis Pharma Gmbh | $42.09 | 2019 | |
| Shire North American Group INC | $40.64 | 2019 | |
| Optinose US, INC. | $38.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.59 | 2019 | |
| Kaleo, INC. | $32.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.86 | 2019 | |
| Horizon Therapeutics Plc | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Huffaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.